With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...

We report rapid, potent reversal of GalNAc-siRNA-mediated RNA interference (RNAi) activity in vivo with short, synthetic, high-affinity oligonucleotides complementary to the siRNA guide strand. We ...

Vial's INHBE siRNA is a first-in-class, liver-targeted (GalNAc-conjugated) siRNA therapy that silences INHBE and its gene product, Activin E -- Leading key opinion leaders (KOL ...

Genetic, biochemical and structural studies have implicated Argonaute proteins as the catalytic core of the RNAi effector complex, RISC. Here we show that recombinant, human Argonaute2 can combine ...

After raising $33 million back in April, Shanghai-based Rona Therapeutics is using some of that money to acquire a small interfering RNA (siRNA) platform and four preclinical candidates from Sanofi.

SHANGHAI and SANTA BARBARA, Calif., /PRNewswire/ -- Rona Therapeutics, a global leader in next-generation RNAi medicines, ...

A key step to deliver RNAi therapeutics to diverse cell types and tissues beyond the liver from the collaboration of ...

“The copious patentable aspects of a therapeutically efficacious siRNA delivery formulation imply intense patenting activity in the years to come, along with market exclusivity that can be extended ...

Inherited genetic variation in EPHA5, FGD4, and NRDG1 and paclitaxel (P)-induced peripheral neuropathy (PN): Results from a genome-wide association study (GWAS) in CALGB 40101. Background: ...

Transfecting siRNA with a high efficiency won’t be a challenge for you anymore thanks to these tips. siRNA transfection is a powerful tool to understand underlying mechanisms in gene regulation and ...